Guardant Health completed a $550 million private offering of 0% convertible senior notes due 2032. Net proceeds of approximately $538.3 million were used in part to repurchase $395.2 million of its 2027 convertible notes.
GH · Guardant Health, Inc. · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Guardant Health raised full-year 2026 revenue guidance to $1.36 to $1.37 billion, after reporting third-quarter revenue of $361.0 million; screening revenue reached $68 million and oncology revenue reached $231 million.
Guardant Health reported revenue of $361.0 million for the three months ended September 30, 2026, up 36% from $265.2 million for the three months ended September 30, 2025. Shield screening revenue rose 180% to $67.6 million.
Guardant Health reported third-quarter revenue of $361.0 million, up 36%, and raised 2026 revenue guidance to $1.36 to $1.37 billion, representing 38% to 40% growth.
Guardant Health expanded its board to 11 by appointing Kevin R. Sayer effective November 2, 2026, and appointed Robert A. Parks Chief Accounting Officer. Sayer will receive a $500,000 restricted stock unit award and a $60,000 per year cash retainer.
Guardant Health, Inc. awarded founders and Co-CEOs Helmy Eltoukhy and AmirAli Talasaz 465,413 target PSUs each, contingent on relative TSR, with 25% tied to a three-year period and 75% to a five-year period beginning June 1, 2026.